Nexomic was excited to attend BIO US 2026 and engage with leaders across biotechnology, pharma, clinical research, and precision medicine.
The conversations reinforced a clear direction for the industry: the next wave of oncology innovation will depend on better understanding the complex biology behind treatment response, resistance, and patient heterogeneity.
At Nexomic, this is exactly where we are focused. Our platforms are designed to transform multi-omics and clinical data into decision-ready biological intelligence that can support drug development, patient stratification, and smarter oncology strategies.
We are especially excited about the potential partnerships emerging from BIO US and look forward to collaborating with organizations that share our vision of decoding cancer biology to guide better therapeutic decisions.